Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Q2 2024 Results Conference Call July 31, 2024 8:00 AM ET
Company Participants
Alex Sapir - CEO and President
Alan Musso - CFO
Iain Fraser - SVP of Early Development
Conference Call Participants
Corinne Johnson - Goldman Sachs
Kristen Kluska - Cantor Fitzgerald
Joseph Schwartz - Leerink Partners
Dae Gon Ha - Stifel
Gregory Renza - RBC Capital Markets
Matthew Biegler - Oppenheimer
Operator
Good morning and welcome to Fulcrum's Therapeutics Second Quarter 2024 Financial Results and Business Update Conference Call. [Operator Instructions]. This call is being webcast live, and can be accessed on the Investors section of Fulcrum's website at www.fulcrumtx.com, and is being recorded. Please be reminded that remarks made during this call may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
These may include statements about the company's future expectations and plans, clinical development timelines and financial projections. While these forward-looking statements represent Fulcrum's view as of today, this should not be relied upon as representing the company's views in the future. Fulcrum may update these statements in the future, but is not taking on an obligation to do so.
Please refer to Fulcrum's most recent filings with the Securities and Exchange Commission for a discussion of certain risks and uncertainties associated with the company's business. Leading the call today will be Alex Sapir, CEO and President of Fulcrum. Joining Alex on the call are Alan Musso, Chief Financial Officer; Dr. Pat Horn, Chief Medical Officer; and Dr. Iain Fraser, Senior Vice President of Development. After providing updates, on our key programs. There will be a brief Q&A in which Alex, Alan, Pat and Iain will be available to answer your questions.
With that, it's my pleasure to turn the call over to Alex.
Alex Sapir
That's great. Thank you, Lisa, and good morning, everyone, and thanks to all of you for joining us for our second quarter conference call. We've organized today's call to provide you with updates on recent progress and upcoming milestones for our two clinical-stage assets, losmapimod and pociredir. And after a brief introduction, we'll segue into our pipeline, I'll then ask Alan to review the financials. And finally, we'll end by taking your questions.
I am happy to report that we are on track to report top-line data for the Phase 3 REACH trial of losmapimod by the end of October compared to our previous guidance of the fourth quarter. As we advance toward this important inflection point, we continue to build out the team and add talent as we prepare for the potential NDA filing and the U.S. commercial launch of losmapimod. In parallel, we are working with Sanofi in preparation for regulatory filings and the launch of losmapimod outside of the United States.